Core Viewpoint - The company, Zhaoke Ophthalmology-B (06622.HK), has established a strategic partnership with Taiwan-based Dongshenghua Pharmaceutical Co., Ltd. to jointly advance the clinical introduction and future commercialization of BRIMOCHOL™ PF in Taiwan [1] Group 1: Partnership Details - Zhaoke grants Dongshenghua exclusive rights as a distributor in Taiwan for the registration, importation, promotion, distribution, marketing, and sale of BRIMOCHOL™ PF [1] - Dongshenghua specializes in chronic diseases and precision medicine, providing safe and accessible healthcare solutions [1] Group 2: Regulatory Updates - In June 2025, Tenpoint Therapeutics, the developer of BRIMOCHOL™ PF, announced that the U.S. FDA has accepted the new drug application for the product [1] - The FDA has set a review deadline for the Prescription Drug User Fee Act (PDUFA) for BRIMOCHOL™ PF on January 28, 2026 [1]
兆科眼科-B(06622.HK)：就于台湾地区商业化BRIMOCHOL™ PF与东生华制药订立策略性伙伴关系